Published in Nat Rev Drug Discov on March 30, 2012
Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol (2013) 4.33
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med (2013) 1.96
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest (2014) 1.21
Inflammatory monocytes and Fcγ receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice. Proc Natl Acad Sci U S A (2013) 1.14
Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI. Nat Commun (2015) 0.93
Neutrophil-Mediated Phagocytosis of Staphylococcus aureus. Front Immunol (2014) 0.93
SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science (2016) 0.89
The Split Virus Influenza Vaccine rapidly activates immune cells through Fcγ receptors. Vaccine (2014) 0.88
Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3). Mol Cell Proteomics (2015) 0.88
Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. PLoS Pathog (2016) 0.86
Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn. Br J Haematol (2014) 0.85
Human IgG4: a structural perspective. Immunol Rev (2015) 0.85
Immune-complex mimics as a molecular platform for adjuvant-free vaccine delivery. PLoS One (2013) 0.84
CMV-encoded Fcγ receptors: modulators at the interface of innate and adaptive immunity. Semin Immunopathol (2014) 0.84
Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants. PLoS One (2015) 0.83
Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry. Mol Cell Proteomics (2014) 0.83
The contribution of allergen-specific IgG to the development of th2-mediated airway inflammation. J Allergy (Cairo) (2012) 0.83
Human IgG2- and IgG4-expressing memory B cells display enhanced molecular and phenotypic signs of maturity and accumulate with age. Immunol Cell Biol (2017) 0.82
Polymorphisms and interspecies differences of the activating and inhibitory FcγRII of Macaca nemestrina influence the binding of human IgG subclasses. J Immunol (2013) 0.82
Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms. EMBO Mol Med (2015) 0.81
TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity. Immunol Rev (2015) 0.81
Allelic-dependent expression of an activating Fc receptor on B cells enhances humoral immune responses. Sci Transl Med (2013) 0.81
Engineered IgG1-Fc - one fragment to bind them all. Immunol Rev (2016) 0.80
Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. MAbs (2012) 0.80
Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein. EMBO Mol Med (2014) 0.80
Induced expression of FcγRIIIa (CD16a) on CD4+ T cells triggers generation of IFN-γhigh subset. J Biol Chem (2015) 0.79
Restoration of natural killer activity in hepatocellular carcinoma by treatment with antibody against granulin-epithelin precursor. Oncoimmunology (2015) 0.78
How Mouse Macrophages Sense What Is Going On. Front Immunol (2016) 0.78
Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction. World J Gastroenterol (2015) 0.78
On the perplexingly low rate of transport of IgG2 across the human placenta. PLoS One (2014) 0.77
Chemoenzymatic Glyco-engineering of Monoclonal Antibodies. Methods Mol Biol (2015) 0.77
TRIM21 Immune Signaling Is More Sensitive to Antibody Affinity Than Its Neutralization Activity. J Immunol (2016) 0.77
Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant. Immunogenetics (2012) 0.77
CD14(bright)CD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis. Arthritis Res Ther (2017) 0.76
Platelets convert peripheral blood circulating monocytes to regulatory cells via immunoglobulin G and activating-type Fcγ receptors. BMC Immunol (2015) 0.76
IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs. MAbs (2017) 0.76
Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions. J Immunol (2015) 0.76
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function. J Biol Chem (2015) 0.76
Functions of Antibodies. Microbiol Spectr (2014) 0.75
Human CD64-targeted non-viral siRNA delivery system for blood monocyte gene modulation. Sci Rep (2017) 0.75
Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells. Mol Cancer Ther (2016) 0.75
CD32a antibodies induce thrombocytopenia and type II hypersensitivity reactions in FCGR2A mice. Blood (2015) 0.75
Anti-tax interacting protein-1 (TIP-1) monoclonal antibody targets human cancers. Oncotarget (2016) 0.75
Genome-wide gain-of-function screen for genes that induce epithelial-to-mesenchymal transition in breast cancer. Oncotarget (2016) 0.75
Label-free detection of immune complexes with myeloid cells. Clin Exp Immunol (2016) 0.75
Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors. MAbs (2014) 0.75
Specific plasma autoantibody reactivity in myelodysplastic syndromes. Sci Rep (2013) 0.75
Subclass-specific IgG glycosylation is associated with markers of inflammation and metabolic health. Sci Rep (2017) 0.75
Disulfide Bond Characterization of Endogenous IgG3 Monoclonal Antibodies Using LC-MS: An Investigation of IgG3 Disulfide-mediated Isoforms. Anal Methods (2016) 0.75
Role of FcγRIIIA (CD16) in IVIg-mediated anti-inflammatory function. J Clin Immunol (2014) 0.75
Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcγRI. Sci Rep (2017) 0.75
Rapid screening of IgG quality attributes - effects on Fc receptor binding. FEBS Open Bio (2017) 0.75
CD64: An Attractive Immunotherapeutic Target for M1-type Macrophage Mediated Chronic Inflammatory Diseases. Biomedicines (2017) 0.75
FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value? World J Oncol (2015) 0.75
Identification of sequence variants influencing immunoglobulin levels. Nat Genet (2017) 0.75
Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet (2008) 12.51
Fcgamma receptors as regulators of immune responses. Nat Rev Immunol (2008) 11.34
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood (2002) 8.76
Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (2006) 8.13
FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell (1994) 7.66
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol (2003) 6.77
Human neutrophil Fc gamma receptor distribution and structure. Proc Natl Acad Sci U S A (1982) 6.54
Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science (2005) 6.48
FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet (2007) 5.93
High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem (2000) 5.18
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem (2002) 5.10
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (1992) 5.07
Convergent solutions to binding at a protein-protein interface. Science (2000) 4.47
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem (2002) 4.11
Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood (2008) 4.10
Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest (2005) 3.93
Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature (2011) 3.80
Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov (2009) 3.66
Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A (2006) 3.54
The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature (2000) 3.53
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther (2006) 3.46
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol (2009) 3.20
Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood (1997) 3.19
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science (1998) 2.84
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol (2005) 2.82
Fc receptors: rubor redux. Cell (1994) 2.77
Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol (2006) 2.73
Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol (2010) 2.64
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem (2006) 2.58
Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy. Proc Natl Acad Sci U S A (2007) 2.56
Transmembrane signaling: the joy of aggregation. J Immunol (1992) 2.56
Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol (1986) 2.53
FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol (2010) 2.44
Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol (1999) 2.44
The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem (2001) 2.33
FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity (2002) 2.31
A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat Genet (2009) 2.26
Molecular basis of Fc receptor function. Adv Immunol (1994) 2.24
Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng (2004) 2.22
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem (2003) 2.03
Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood (2008) 2.03
Refined structure of an intact IgG2a monoclonal antibody. Biochemistry (1997) 2.02
Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med (1986) 2.01
Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol (2005) 1.94
Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J Exp Med (1999) 1.92
Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha. Nature (2000) 1.90
Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol (2007) 1.89
Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res (2005) 1.88
Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). Biochemistry (2000) 1.87
The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem (2005) 1.85
Antibody-mediated modulation of immune responses. Immunol Rev (2010) 1.84
Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med (2006) 1.80
Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci (2009) 1.79
Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum (2002) 1.79
Human antibody effector function. Adv Immunol (1992) 1.78
Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody. J Exp Med (1986) 1.75
Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol (2004) 1.74
Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet (1993) 1.72
FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity (2002) 1.72
A novel polymorphism in the Fcgamma receptor IIB (CD32B) transmembrane region alters receptor signaling. Arthritis Rheum (2003) 1.71
Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood (2003) 1.61
Clinical uses of intravenous immunoglobulin. Clin Exp Immunol (2005) 1.61
CD16 promotes Escherichia coli sepsis through an FcR gamma inhibitory pathway that prevents phagocytosis and facilitates inflammation. Nat Med (2007) 1.57
Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcgammaRII. Curr Biol (2000) 1.56
Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med (2006) 1.55
Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria. Proc Natl Acad Sci U S A (2007) 1.55
Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng (2006) 1.54
Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc. Nature (2003) 1.53
Inhibition of immune responses by ITAM-bearing receptors. Sci STKE (2006) 1.50
Fcγ receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk (2010) 1.49
Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog (2005) 1.49
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res (2007) 1.48
Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases. Immunity (2008) 1.47
Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol (2007) 1.47
Monoclonal antibodies and synthetic peptides define the active site of FcepsilonRI and a potential receptor antagonist. Allergy (2000) 1.45
Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol (2011) 1.44
Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells. Proc Natl Acad Sci U S A (2011) 1.44
In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci U S A (2008) 1.44
The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol (2010) 1.43
Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol (2009) 1.42
FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J Immunol (2006) 1.42
Copy number, linkage disequilibrium and disease association in the FCGR locus. Hum Mol Genet (2010) 1.41
The Clq receptor site on immunoglobulin G. Nature (1980) 1.40
The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease. Adv Immunol (2004) 1.38
In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res (2010) 1.37
Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol (2002) 1.36
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood (2011) 1.34
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol (2006) 1.32
Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci U S A (2008) 1.31
Crystal structure of the human leukocyte Fc receptor, Fc gammaRIIa. Nat Struct Biol (1999) 1.29
The human low affinity Fcgamma receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. J Biol Chem (2001) 1.28
Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy. Immunity (2011) 1.27
Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci U S A (2006) 1.26
Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol (2011) 1.23
Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. J Biol Chem (2001) 1.21
Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs (2010) 1.21
The human mononuclear phagocyte high-affinity Fc receptor, FcRI, defined by a monoclonal antibody, 10.1. Eur J Immunol (1987) 1.20
Inhibitory ITAM signaling traps activating receptors with the phosphatase SHP-1 to form polarized "inhibisome" clusters. Sci Signal (2011) 1.19
Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol (2004) 2.33
Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res (2006) 1.33
Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy. Vaccine (2006) 1.16
Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. Methods (2006) 1.11
Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur J Immunol (2008) 1.10
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res (2006) 1.03
Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology (2006) 1.03
Cripto: a novel target for antibody-based cancer immunotherapy. Cancer Res (2004) 1.01
Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design. J Mol Biol (2002) 0.96
Reactive oxygen species level defines two functionally distinctive stages of inflammatory dendritic cell development from mouse bone marrow. J Immunol (2010) 0.93
Cell-penetrating peptides: application in vaccine delivery. Biochim Biophys Acta (2009) 0.92
The adjuvanticity of a mannosylated antigen reveals TLR4 functionality essential for subset specialization and functional maturation of mouse dendritic cells. J Immunol (2008) 0.91
Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. Immunotherapy (2013) 0.88
Molecular basis of improved immunogenicity in DNA vaccination mediated by a mannan based carrier. Biomaterials (2008) 0.84
Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses. Vaccine (2006) 0.84
Dendritic cell vaccination. Expert Rev Vaccines (2007) 0.83
Receptor-mediated delivery of antigens to dendritic cells: anticancer applications. Mol Pharm (2007) 0.83
Polymorphisms and interspecies differences of the activating and inhibitory FcγRII of Macaca nemestrina influence the binding of human IgG subclasses. J Immunol (2013) 0.82
Tetraspanin CD37 contributes to the initiation of cellular immunity by promoting dendritic cell migration. Eur J Immunol (2013) 0.82
An FcgammaRIIa-binding peptide that mimics the interaction between FcgammaRIIa and IgG. Mol Immunol (2007) 0.82
Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide. Immunology (2006) 0.81
Intracellular detection and immune signaling pathways of DNA vaccines. Expert Rev Vaccines (2009) 0.79
Penetratin tandemly linked to a CTL peptide induces anti-tumour T-cell responses via a cross-presentation pathway. Immunology (2006) 0.79
Synthesis and study of the electrophoretic behavior of mannan conjugates with cyclic peptide analogue of myelin basic protein using lysine-glycine linker. Anal Biochem (2005) 0.78
Mannan-mediated gene delivery for cancer immunotherapy. Immunology (2007) 0.78
Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses. Vaccine (2008) 0.78
A membrane penetrating multiple antigen peptide (MAP) incorporating ovalbumin CD8 epitope induces potent immune responses in mice. Biochim Biophys Acta (2010) 0.77
Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways. Immunol Cell Biol (2011) 0.76
Aspects of cancer immunotherapy. Immunol Cell Biol (2003) 0.76
Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors. Expert Rev Vaccines (2008) 0.75